Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 12/20 | 0.43 |
| ▸ | JAK2 | O60674 | 6/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21097343 | 1.00 | PTGS1 (0.44) | PTGS1PTGS2PIK3C3NTRK1JAK2 | |
| SCHEMBL21097316 | 0.83 | NTRK1 (0.47) | PIK3C3NTRK1JAK2 | |
| SCHEMBL21097315 | 0.83 | NTRK1 (0.47) | PIK3C3NTRK1JAK2 | |
| SCHEMBL21097329 | 0.81 | NTRK1 (0.49) | NTRK1JAK2 | |
| SCHEMBL21097332 | 0.81 | NTRK1 (0.49) | NTRK1JAK2 | |
| SCHEMBL28129544 | 0.80 | NTRK1 (0.47) | PIK3C3NTRK1JAK2 | |
| SCHEMBL21097294 | 0.80 | NTRK1 (0.44) | PIK3C3NTRK1JAK2 | |
| SCHEMBL21097293 | 0.80 | NTRK1 (0.44) | PIK3C3NTRK1JAK2 | |
| SCHEMBL21097341 | 0.80 | NTRK1 (0.44) | PIK3C3NTRK1JAK2 | |
| SCHEMBL21097337 | 0.80 | NTRK1 (0.44) | PIK3C3NTRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344031-B2 | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2019-07-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344031-B2 | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors | MUSK, DMPK, PNCK | PTGS1 2829/4885PTGS2 3611/4885PIK3C3 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.